Research Topics
Species | D KragSummaryAffiliation: University of Vermont Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patientsGlenn Deng
Biology, Genetix USA Inc, 120 Baytech Drive, San Jose, CA 95134, USA
Breast Cancer Res 10:R69. 2008..However, some tumor cells express low or no EpCAM. Here we present a highly sensitive and reproducible enrichment method that is based on binding to anti-CK alone or a combination of anti-CK and anti-EpCAM antibodies...- Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferationCorrine J Porter
School of Biomedical and Chemical Sciences, University of Western Australia, WA 6009, Australia
BMC Struct Biol 7:58. 2007..Recently, an inhibitory peptide (G7-18NATE) has been developed which binds specifically to the Grb7 SH2 domain and is able to attenuate cancer cell proliferation and migration in various cancer cell lines... - Phage-displayed random peptide libraries in mice: toxicity after serial panningDavid N Krag
Department of Surgery, College of Medicine and the Vermont Comprehensive Cancer Center, Given Bldg Rm E309, Burlington, VT 05405, USA
Cancer Chemother Pharmacol 50:325-32. 2002..With the ultimate goal of developing similar methods for treating human cancer, we describe an in vivo RPL screening process that, unlike previous in vivo experiments, does not harm the animal being screened... - Current status of sentinel node surgery in breast cancerDavid N Krag
University of Vermont, College of Medicine, Burlington, Vermont, USA
Oncology (Williston Park) 17:1663-6; discussion 1669-70, 1675-6. 2003..The completion of clinical trials establishing that no meaningful reduction in survival is associated with the decrease in side effects is important... - NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trialDavid N Krag
Department of Surgery, University of Vermont, Burlington, Vermont, USA
Ann Surg Oncol 11:208S-10S. 2004..A secondary aim of the B32 trial is to evaluate whether patients with "occult" metastases in the SNs have worse survival. Accrual is taking place at 73 institutions in North America, and 217 surgeons are enrolling patients... - Breast cancer and the NSABP-B32 sentinel node trialDavid Krag
Department of Surgical Oncology, University of Vermont College of Medicine Given Bldg Rm E309 Burlington, VT 05405, USA
Breast Cancer 11:221-4; discussion 264-6. 2004 - Cytokeratin-positive cells in the bone marrow of breast cancer patients and noncancer donorsDavid N Krag
Department of Surgery, University of Vermont College of Medicine, Burlington, VT 05401, USA
Appl Immunohistochem Mol Morphol 17:403-8. 2009..It is important to devise improved criteria and methods for accurate detection and interpretation of disseminated tumor cells in the marrow of breast cancer patients... - The detection of isolated tumor cells in bone marrow comparing bright-field immunocytochemistry and multicolor immunofluorescenceDavid N Krag
Department of Surgery, University of Vermont College of Medicine, Given Building, 89 Beaumont Avenue, Burlington, Vermont, 05405, USA
Ann Surg Oncol 12:753-60. 2005..However, this method can result in false-positive staining events. We used multicolor immunofluorescence (IF) to develop a more specific assay for detecting isolated tumor cells in marrow samples from breast cancer patients... - Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trialDavid N Krag
University of Vermont, College of Medicine, Burlington, VT 05405 0068, USA
Lancet Oncol 8:881-8. 2007..The aim of this paper is to report the technical success and accuracy of SLN resection plus ALND versus SLN resection alone... - Breast cancer survival according to number of nodes removedDavid N Krag
College of Medicine, University of Vermont, Burlington, Vermont 05405, USA
Ann Surg Oncol 10:1152-9. 2003.... - Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialDavid N Krag
National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
Lancet Oncol 11:927-33. 2010.... - Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trialDavid N Krag
Department of Surgery, College of Medicine, University of Vermont, Given Building, Rm E309, 89 Beaumont Ave, Burlington, VT 05405, USA
J Natl Cancer Inst 101:1356-62. 2009..We evaluated the relationship of surgeon trial preparation, protocol compliance audit, and technical outcomes... - Why perform randomized clinical trials for sentinel node surgery for breast cancer?D Krag
Department of Surgery, University of Vermont, College of Medicine, Given Building, Burlington, VT 05405, USA
Am J Surg 182:411-3. 2001.... - Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7Stephanie C Pero
Department of Surgery and the Vermont Cancer Center, University of Vermont School of Medicine, Burlington, Vermont 05405, USA
J Biol Chem 277:11918-26. 2002..These peptides will be useful in the development of targeted molecular therapeutics for cancers overexpressing Grb7 and in the development of Grb7-specific inhibitors to gain a complete understanding of the physiological role of Grb7... - Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32Stephanie R Land
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistics Center, University of Pittsburgh, Pittsburgh, PA 15213, USA
J Clin Oncol 28:3929-36. 2010..We report the definitive patient-reported outcomes (PRO) comparisons... - Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cellsStephanie C Pero
Department of Surgery, Vermont Comprehensive Cancer Center, College of Medicine, University of Vermont, Burlington, VT 05405, USA
Int J Cancer 111:951-60. 2004..Continuing research with this peptide includes increasing its affinity to ErbB2, evaluation of pharmacokinetics and evaluation of anti-proliferative effects with conjugate anti-cancer agents... - Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimensGirja S Shukla
Department of Surgery, Vermont Comprehensive Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA
J Drug Target 13:7-18. 2005..These protocols have direct application to screen for tumor-binding ligands with small tumor tissue specimens... - Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategyDonald L Weaver
Department of Pathology, University of Vermont College of Medicine, Burlington, VT 05405 0068, USA
Am J Surg Pathol 33:1583-9. 2009..7 to 4.8 mm) and the modal thickness was 2.3 mm. Although more comprehensive sectioning of SLNs detects additional micrometastases, the data suggest diminishing returns and reduced cost effectiveness for the comprehensive strategy... - Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissectionTakamaru Ashikaga
University of Vermont College of Medicine, Burlington, Vermont 05405, USA
J Surg Oncol 102:111-8. 2010.... - Cancer cell-specific internalizing ligands from phage displayed beta-lactamase-peptide fusion librariesGirja S Shukla
Department of Surgery and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA
Protein Eng Des Sel 23:431-40. 2010..This is first report on the selection of cell-internalized enzyme conjugates using phage display technology, which opens the possibility for new fusion libraries with other relevant enzymes... - Developing bifunctional beta-lactamase molecules with built-in target-recognizing module for prodrug therapy: identification of Enterobacter Cloacae P99 cephalosporinase loops suitable for randomization and phage-display selectionGirja S Shukla
Department of Surgery and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA
J Mol Recognit 22:425-36. 2009..This is an enabling step in our long-term goal of developing bifunctional beta-lactamase molecules against cancer-specific targets for enzyme prodrug therapy of cancer... - Phage-displayed combinatorial peptide libraries in fusion to beta-lactamase as reporter for an accelerated clone screening: Potential uses of selected enzyme-linked affinity reagents in downstream applicationsGirja S Shukla
Department of Surgery and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, 05405, USA
Comb Chem High Throughput Screen 13:75-87. 2010..Target-specific beta-lactamase-linked affinity reagents selected by this procedure can be produced in bulk, purified, and used, without any modification, for a variety of downstream applications, including targeted prodrug therapy... - Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapyGirja S Shukla
Department of Surgery and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA
J Drug Target 18:115-24. 2010..Furthermore, these affinity reagents have also a potential for their direct use in the targeted enzyme prodrug therapy of cancer... - Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cellsGirja S Shukla
Department of Surgery, Vermont Comprehensive Cancer Center, and University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405, USA
Int J Cancer 120:2233-42. 2007..It is expected that a similar approach will be useful in developing tumor-targeting molecules of several other enzyme candidates of cancer prodrug therapy... - Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 quality assurance studyDonald L Weaver
Department of Pathology, College of Medicine, University of Vermont, Burlington, Vermont 05405 0068, USA
Cancer 107:661-7. 2006..2 mm but not larger than 2.0 mm) or isolated tumor cell clusters (< or = 0.2 mm). This study defines the rate at which pathologists miss metastases on CK IHC of sentinel lymph nodes (SLN)... - Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancerDonald L Weaver
University of Vermont, Vermont Cancer Center and Fletcher Allen Health Care, Burlington, Vermont 05405 0068, USA
Mod Pathol 16:1159-63. 2003..Metastases identified exclusively by computer-assisted cell detection tend to be extremely small, and the clinical significance of their identification is currently unknown... - Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breSeth P Harlow
Department of Surgery, University of Vermont College of Medicine and the Vermont Cancer Center, Burlington 05405, USA
Ann Surg 241:48-54. 2005..To train surgeons in a standardized technique of sentinel lymph node biopsy and to prepare them for the requirements of a prospective randomized surgical trial... - Selection of tumor-targeting agents on freshly excised human breast tumors using a phage display libraryGirja S Shukla
Department of Surgery, Vermont Comprehensive Cancer Center, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405, USA
Oncol Rep 13:757-64. 2005..This is an important enabling step in identifying lead molecules for developing novel, specific, and effective agents that can be used for the diagnosis and treatment of cancer... - Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention TrialMary Cushman
Department of Medicine, University of Vermont, Burlington, VT, USA
Br J Haematol 120:109-16. 2003..Reductions of antithrombin and protein S, but not protein C or APC resistance, might relate to the increased risk of venous thrombosis associated with tamoxifen treatment... - A sensitive and rapid chemiluminescence ELISA for filamentous bacteriophagesGirja S Shukla
Department of Surgery, Vermont Comprehensive Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA
J Immunoassay Immunochem 26:89-95. 2005..In conclusion, the Ff titration method presented here is highly sensitive, rapid, and amenable to high throughput analysis... - Grb7-based molecular therapeutics in cancerStephanie C Pero
Department of Surgery and the Vermont Cancer Center, University of Vermont School of Medicine, Given Medical Building, Burlington, VT 05405, USA
Expert Rev Mol Med 5:1-11. 2003..Grb7 is overexpressed in breast, oesophageal and gastric cancers, and may contribute to the invasive potential of cancer cells. Molecular interactions involving Grb7 therefore provide attractive targets for therapeutic intervention... - Selective delivery of therapeutic agents for the diagnosis and treatment of cancerGirja S Shukla
Vermont Comprehensive Cancer Center, Department of Surgery, University of Vermont College of Medicine, Burlington, VT 05405, USA
Expert Opin Biol Ther 6:39-54. 2006..This paper discusses recent developments and future prospects of targeted delivery technologies in the management of cancer... - Quality measures for breast cancer surgery: initial validation of feasibility and assessment of variation among surgeonsLaurence E McCahill
Department of Surgery, Division of Surgical Oncology, University of Vermont, Burlington, VT 05405, USA
Arch Surg 144:455-62; discussion 462-3. 2009..To identify and quantify surgical outcomes as possible quality measures of initial breast cancer surgery and to assess variation among surgeons... - Minimal invasive staging for breast cancer: clinical experience with sentinel lymph node biopsyD Krag
Department of Surgery, University of Vermont, Given Building, Burlington, VT 05405-0068, USA
Semin Oncol 28:229-35. 2001..Successful application of SN surgery should allow elimination of conventional axillary lymphadenectomy in at least 75% of patients with breast cancer. Semin Oncol 28:229-235... - Intraoperative ultrasound versus mammographic needle localization for ductal carcinoma in situT A James
Department of Surgery, University of Vermont, Burlington, VT, USA
Ann Surg Oncol 16:1164-9. 2009..The purpose of this study was to compare the efficacy of intraoperative ultrasound versus mammographic needle localization (MNL) for partial mastectomy in DCIS... - Selection of tumor-binding ligands in cancer patients with phage display librariesDavid N Krag
Department of Surgery and Vermont Cancer Center, University of Vermont College of Medicine, E309 89 Beaumont Avenue, Burlington, VT 05405, USA
Cancer Res 66:7724-33. 2006..The lack of toxicity and the ability to recover clones with favorable characteristics are a first step for further research with this technology in cancer patients... - Pathological and molecular assessment of sentinel lymph nodes in solid tumorsDavid N Krag
Department of Surgery, Vermont Cancer Center, College of Medicine, University of Vermont, Burlington, VT 05405, USA
Semin Oncol 29:274-9. 2002..It is critical that pathologists and clinicians conduct definitive clinical research directed toward defining the role and impact that SN surgery has on each of these surgical goals... - Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excisionHeather L Evans
Department of Surgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA
Ann Surg Oncol 10:416-25. 2003..Patients have traditionally been considered candidates for sentinel node biopsy (SNBx) only at the time of wide local excision (WLE). We hypothesized that patients with prior WLE may also be staged accurately with SNBx... - Phage-display selection on tumor histological specimens with laser capture microdissectionYujing Sun
Department of Surgery, Vermont Comprehensive Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA
J Immunol Methods 347:46-53. 2009..This may speed the process of generating ligands to any subset of cells or noncellular feature present on histological specimens... - Identification of single chain antibodies to breast cancer stem cells using phage displayDeniz Gur
Department of Surgery, Vermont Comprehensive Cancer Center, University of Vermont, College of Medicine, Burlington, VT 05405, USA
Biotechnol Prog 25:1780-7. 2009.... - Nuclear medicine and the surgeonD Krag
Department of Surgery, University of Vermont, Burlington 05405 0068, USA
Lancet 354:1019-22. 1999.... - Practice patterns of sentinel node biopsy at five comprehensive cancer centersDavid N Krag
J Natl Cancer Inst 95:1498-9. 2003 - Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasisShinji Tanaka
Department of Hepato Biliary Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, 1 5 45 Yushima, Tokyo 113 8519, Japan
J Natl Cancer Inst 98:491-8. 2006..In this study, we evaluated Grb7 protein as a molecular target of therapy for metastatic pancreatic cancer... - Is axillary dissection needed when the sentinal node is positive? Yes!David N Krag
J Surg Oncol 97:197-8. 2008 - Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1Peng Li
Laboratory of Medicinal Chemistry, CCR, NCI Frederick, NIH, Frederick, MD 21702, USA
Biopolymers 87:225-30. 2007..This synthetic approach provides a general method for conjugating a highly functionalized and disulfide-bridge containing cyclopeptide to Taxol or other antitumor agents...
Research Grants
- Sentinel Node Versus Axillary Dissection in Breast CancerDavid Krag; Fiscal Year: 2009....
- Targeted Enzymes for Prodrug TherapyDavid Krag; Fiscal Year: 2007..Successful completion of these experiments will result in demonstration of novel targeted effector molecules that bind selectively to tumors and activate cytotoxic prodrugs. ..
- Sentinel Node Versus Axillary Dissection in Breast CancerDavid Krag; Fiscal Year: 2007....
- TARGETING BREAST CANCER WITH SMALL LIGANDSDavid Krag; Fiscal Year: 2006..3) Use the structure-based, homologous analog and biased library approach to make educated designs to increase the affinity of the Grb7 ligands ..
- In Vivo Selection of Ligands for Targeted TherapyDavid Krag; Fiscal Year: 2003..Successful completion of this clinical study will result in demonstration of a satisfactory safety profile and short peptides that bind selectively to tumor tissue. ..
- TARGETING BREAST CANCER WITH SMALL LIGANDSDavid Krag; Fiscal Year: 2001..Specifically, this work will produce lead compounds for drugs with great potential efficacy in the treatment of breast cancer. ..
- Sentinel Node Versus Axillary Dissection in Breast CancerDavid N Krag; Fiscal Year: 2010....